Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET
Company Participants
Bill Peters - CFO
Dan Dischner - SVP of Corporate Communications
Conference Call Participants
Ekaterina Knyazkova - JPMorgan
Pavan Patel - Bank of America
David Amsellem - Piper Sandler
Operator
Greetings and welcome to the Amphastar Pharmaceuticals Inc. Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for future periods are forward-looking statements.
These statements are based solely on information that is now available to us. We encourage you to review the section entitled forward-looking statements in the press release issued today and the presentation on the company's website. Also, please refer to our SEC filings which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance. We will also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliations to U.S. GAAP may be found in our earnings release. Please note, this conference call is being recorded.
Our speakers today are Mr. Bill Peters, CFO; Mr. Dan Dischner, Senior Vice President of Corporate Communications; and Mr. Tony Marrs, Executive Vice President of Regulatory Affairs and Clinical Operations.
I will now turn the conference over to your host, Mr. Dan Dischner, Senior Vice President of Corporate Communications. Dan, you may begin.
Dan Dischner
Thank you, Zico. Good afternoon, and thanks for joining us for our third quarter's earnings call of 2024. Today, I'm joined by Bill Peters, our CFO and Executive Vice President of Finance and Tony Marrs, Executive Vice President of Regulatory Affairs and Clinical Operations.
In the Q3 of 2024, Amphastar reported net revenues of $191.2 million marking a 6% increase year-over-year, reflecting the resilience and growing strength of our diversified product portfolio and the strategic initiatives. Despite facing challenges such as the impact of Hurricane Helane, which impacted our logistics and resulted in delays and delayed shipments, the core business of Amphastar remains robust, leading the path to end this year with a solid footing for the execution of our portfolio.
Our strategic initiatives regarding our regulatory filings and commercial portfolio execution remain on track and we are well positioned to continue the growth of our key revenue drivers with BAQSIMI, Primatene Mist and our core hospital and clinical use products in the critical care arena.